How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,960 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Squamous cell carcinoma of the skin

Squamous cell carcinoma of the skin Squamous cell carcinoma of the skin - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Squamous cell carcinoma of the skin Last reviewed: February 2019 Last updated: August 2018 Summary Malignant tumour of keratinocytes arising in the epidermis of the skin. Second most common non-melanoma skin cancer worldwide, secondary to basal cell carcinoma. Cumulative ultraviolet exposure, most (...) commonly from the sun, and immunosuppression are major risk factors. Treatments include non-surgical destruction (e.g., using cryotherapy), topical chemotherapy, traditional surgical excision, and Mohs micrographic surgery. Definition Cutaneous squamous cell carcinoma (SCC) is the proliferation of atypical, transformed keratinocytes in the skin with malignant behaviour. It ranges from in situ tumours (also known as Bowen's disease) to invasive tumours and metastatic disease. [Figure caption

2018 BMJ Best Practice

2. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Comparative Effectiveness Review Number 199 Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Evidence Summary Introduction Skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common malignancies in the United States. 1 BCC and SCC, the 2 most common skin cancers, are collectively referred to as keratinocyte carcinomas. Over 5.4 million of these lesions are diagnosed (...) in square brackets. RoB = risk of bias; BCC = basal cell carcinoma; SCCIS = squamous cell carcinoma in situ; MMS = Mohs micrographic surgery; PDT = photodynamic therapy; RCT = randomized controlled trial; NRCS = nonrandomized comparative study; CI = confidence interval Table E. Summary conclusions for SCCIS lesions and strength of the relevant evidence (continued)References 1. Centers for Disease Control and Prevention Skin Cancer Statistics. 2015. http://www.cdc.gov/cancer/skin/statistics/index. htm. 2

2017 Effective Health Care Program (AHRQ)

3. Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma)

Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma) Clinical practice guidelines for keratinocyte cancer - Clinical Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Bowel cancer Lung cancer Prostate cancer Skin cancer Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer

2020 Cancer Council Australia

4. Risk of basal cell carcinoma, squamous cell carcinoma, or melanoma skin cancers in users of antihypertensive medications compared to non-users

Risk of basal cell carcinoma, squamous cell carcinoma, or melanoma skin cancers in users of antihypertensive medications compared to non-users Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models

2019 PROSPERO

5. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma Cemiplimab for treating metastatic or Cemiplimab for treating metastatic or locally advanced cutaneous squamous locally advanced cutaneous squamous cell carcinoma cell carcinoma T echnology appraisal guidance Published: 7 August 2019 www.nice.org.uk/guidance/ta592 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

6. ASTRO Guideline on Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin

. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials but there still may be consensus that the benefits of a treatment or diagnostic test clearly outweigh its risks and burden. 6 ASTRO Radiation for Basal and Squamous Cell Cancers Guideline Practical Radiation Oncology 1. Introduction Skin cancer is the most prevalent cancer type in the United States with an incidence rate of over 5 million cases annually. 1 Basal cell carcinoma (BCC) and cutaneous (...) squamous cell carcinoma (cSCC) account for over 95% of all skin cancer diagnoses. A variety of treatment options are available and include surgical excision, cryotherapy, radiation therapy (RT), and topical agents. Although surgical excision is considered to be the primary treatment approach for curative treatment of BCC and cSCC, RT can play an integral role in both the definitive and adjuvant settings. The role of RT for BCC and cSCC has been poorly defined owing to lack of high-quality evidence

2020 American Society for Radiation Oncology

7. Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? Full Text available with Trip Pro

Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? Second primary cancers (SPCs) are becoming a common cancer entity, which may interfere with survival in relatively benign first primary cancers. We examined the hypothesis that immune dysfunction may contribute to SPCs by assessing SPCs associated with known immune responsive skin cancers, invasive and in situ squamous cell carcinoma (...) , Kaposi sarcoma, and Merkel cell carcinoma. Cancers were identified from the Swedish Cancer Registry from the year 1958 to 2015. Standardized relative risks were calculated bidirectionally for any SPC after skin cancer and for skin cancer as SPC. Over 80,000 first primary cancers were identified for each invasive and in situ squamous cell carcinoma of the skin. Bidirectional increased risks were observed for 26 cancers associated with invasive skin cancer; the Spearman rank correlation was 0.72 (P

2019 Journal of Investigative Dermatology

8. Cemiplimab (Libtayo) - cutaneous squamous cell carcinoma

and why it is authorised in the EU What is Libtayo and what is it used for? Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). It is used in patients who cannot have surgery or treatment with radiation to cure their disease. Libtayo contains the active substance cemiplimab. How is Libtayo used? Treatment (...) (life-threatening reactions with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals) have been reported with Libtayo. For the full list of side effects and restrictions with Libtayo, see the package leaflet. Why is Libtayo authorised in the EU? Libtayo is effective at treating cutaneous squamous cell carcinoma, a cancer with few treatment options once it has spread. However, the study involved a small number of patients and additional data are required

2019 European Medicines Agency - EPARs

9. Cemiplimab (Libtayo) - for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

guidelines for the management of the patient with primary cutaneous squamous cell carcinoma in 2002. 9 The guidance was subsequently updated in 2009 and is currently being reviewed. The European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) published Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus- based interdisciplinary guideline in 2015. 10 (...) A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European journal of cancer (Oxford, England : 1990). 2015;51(14):1989- 2007. Epub 2015/07/30. This assessment is based on data submitted by the applicant company up to and including 11 October 2019. *Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the SMC on guidelines

2020 Scottish Medicines Consortium

10. Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy?

research. www.acfp.ca November 25, 2019 (en français) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? Clinical Question: Does hydrochlorothiazide increase the risk of squamous cell carcinoma (SCC) of the skin? Bottom Line: Observational data suggest an association between hydrochlorothiazide and the risk of SCC. Causation has not been proven. Risk appears to consistently increase with dose and duration (example: 5 years of use increases risk 3-4 times). Baseline (...) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? 1 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care

2019 Tools for Practice

11. Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24

Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24 1 Translation of addendum A17-54 Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs) – Addendum zum Auftrag A17-24 (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 October 2017 1.0 Commission: A17-54 Version: Status (...) : IQWiG Reports – Commission No. A17-54 Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 1 Addendum A17-54 Version 1.0 Nivolumab – Addendum to Commission A17-24 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 Commissioning agency: Federal Joint Committee

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. (Abstract)

Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. Koebnerized non-melanoma skin cancer following skin trauma represents a rare and obscure event.To study molecular pathological parameters in koebnerized squamous cell carcinomas (K-SCCs) occurring after complete tumour removal.We assessed two patients with multiple sclerosis who were on treatment with dimethylfumarate (DMF) preceded (...) by long-term azathioprine therapy. Both patients rapidly developed several K-SCCs following histopathologically proven complete excision of cutaneous SCCs. We performed immunohistochemistry for p53, p16, Ki-67, TET-2, IDH-2, 5-hmc and 5-mc. PCR was carried out for the detection of human papilloma viruses. Mutation analysis was performed for BRAF, K-RAS and EGFR.All lesions investigated were negative for HPV DNA. Mutations were not detected. Healthy appearing skin of both patients showed relatively

2018 Journal of the European Academy of Dermatology and Venereology

13. Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. Full Text available with Trip Pro

Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. 29797668 2019 01 18 1468-3083 33 1 2019 Jan Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell (...) carcinomas following skin surgery. e3-e4 10.1111/jdv.15084 Nwabudike L C LC N. Paulescu Institute, Bucharest, Romania. Tatu A L AL Medical and Pharmaceutical Research Unit/Competitive, Interdisciplinary Research Integrated Platform "Dunărea de Jos", ReForm-UDJG, Dermatology, Faculty of Medicine and Pharmacy, Pharmacology Sciences Department, University "Dunarea de Jos", Galati, Romania. eng Letter 2018 06 07 England J Eur Acad Dermatol Venereol 9216037 0926-9959 2018 5 26 6 0 2018 5 26 6 0 2018 5 26 6 0

2018 Journal of the European Academy of Dermatology and Venereology

14. Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma Full Text available with Trip Pro

Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma The glycome of one of the largest and most exposed human organs, the skin, as well as glycan changes associated with non-melanoma skin cancers have not been studied in detail to date. Skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most frequent types of cancers with rising incidence rates in the aging population. We investigated the healthy human (...) skin N- and O-glycome and its changes associated with BCC and SCC. Matched patient samples were obtained from frozen biopsy and formalin-fixed paraffin-embedded tissue samples for glycomics analyses using two complementary glycomics approaches: porous graphitized carbon nano-liquid chromatography electro spray ionization tandem mass spectrometry and capillary gel electrophoresis with laser induced fluorescence detection. The human skin N-glycome is dominated by complex type N-glycans that exhibit

2018 Frontiers in oncology

15. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

if it is not treated. Squamous cell carcinoma (SCC) is the second most common type of skin cancer in the UK. It may spread into local lymph nodes and metastasise to other parts of the body. Current treatments for BCC and SCC include surgical excision and radiotherapy, and less commonly curettage, cryotherapy and chemotherapy. The OPCS-4 codes for Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma are: The relevant procurement/delivery codes in categories X70-X72 (depending (...) Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478) Overview | Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma | Guidance | NICE Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma Interventional procedures guidance [IPG478] Published date: February 2014 Share Save Guidance The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

16. Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report Full Text available with Trip Pro

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report 29556584 2018 11 14 2452-1094 3 1 2018 Jan-Mar Advances in radiation oncology Adv Radiat Oncol Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report. 76-80 10.1016/j.adro.2017.09.006 Cerra-Franco Alberto A Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana

2017 Advances in radiation oncology

17. A systematic review of oral skin cancer prophylaxis: the impact of Acitretin on the occurrence of basal and squamous cell carcinoma

A systematic review of oral skin cancer prophylaxis: the impact of Acitretin on the occurrence of basal and squamous cell carcinoma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units

2019 PROSPERO

18. Evaluation of beta human papillomavirus in skin squamous cell carcinomas in immunosuppressed subjects: a systematic review

Evaluation of beta human papillomavirus in skin squamous cell carcinomas in immunosuppressed subjects: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

19. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Full Text available with Trip Pro

Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Early accurate detection of all skin cancer types is essential to guide appropriate management, reduce morbidity and improve survival. Basal cell carcinoma (BCC) is usually localised to the skin but has potential to infiltrate and damage surrounding tissue, while cutaneous squamous cell carcinoma (cSCC) and melanoma have a much higher potential to metastasise and ultimately lead to death. Exfoliative (...) scrape can never give the same information as a skin biopsy, however, so it is important to better understand in which skin cancer situations it may be helpful.To determine the diagnostic accuracy of exfoliative cytology for detecting basal cell carcinoma (BCC) in adults, and to compare its accuracy with that of standard diagnostic practice (visual inspection with or without dermoscopy). Secondary objectives were: to determine the diagnostic accuracy of exfoliative cytology for detecting cSCC

2018 Cochrane

20. Comparison of P53 Intensity, Frequency and Size in Normal Skin Periphery of Squamous Cell Carcinoma, Basal Cell Carcinoma And Melanocytic Nevus in Persian Skin Type Full Text available with Trip Pro

Comparison of P53 Intensity, Frequency and Size in Normal Skin Periphery of Squamous Cell Carcinoma, Basal Cell Carcinoma And Melanocytic Nevus in Persian Skin Type Non-Melanoma Skin Cancer (NMSC), the most prevalent types being Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC), is the most common type of malignancy in human beings. These neoplasms are more frequent in the elderly and fair skinned people and mainly occur on sun-exposed sites of the body. Ultraviolet B (UVB) has (...) a well-known effect in induction and promotion of growth of these cancers. The p53 tumor suppressor gene is believed to be an early target in UV-induced skin carcinogenesis. Aggregates of keratinocytes with p53 protein overexpression are frequently identified in normal human skin and are more prevalent in chronically sun-exposed skin, and have been proposed to play a role in skin cancer pathogenesis. The aim of this study was to clarify the potential role of P53 in the development

2017 Iranian Journal of Pathology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>